How Much Ozempic Should I Take: The FDA Protocol, Clinical Titration Logic, and When to Deviate

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The FDA-approved starting dose is 0.25 mg once weekly for 4 weeks, escalating to 0.5 mg, then 1 mg, with a maximum of 2 mg for glycemic control
• The 0.25 mg starting dose is a tolerance-building phase, not a therapeutic dose for weight loss or diabetes management
• Most patients reach their effective dose between 0.5 mg and 1 mg; only 30% of patients in clinical trials required escalation to 2 mg
• Staying at a lower dose longer is clinically appropriate if you're seeing results and tolerating the medication well

Direct answer (40-60 words)

The standard Ozempic dosing protocol starts at 0.25 mg once weekly for 4 weeks, escalates to 0.5 mg for at least 4 weeks, then to 1 mg. The maximum FDA-approved dose is 2 mg weekly. Your provider determines the right maintenance dose based on glycemic control, weight-loss response, and side-effect tolerance. Most patients maintain on 0.5 mg to 1 mg long-term.

Table of contents

1. The FDA-approved dosing schedule
2. Why the starting dose is 0.25 mg (and why it won't do much)
3. The clinical logic behind 4-week intervals
4. What "maintenance dose" actually means
5. The dose-response data: how much more weight loss at higher doses
6. When staying at 0.5 mg is the right call
7. The 2 mg question: who needs it and who doesn't
8. Compounded semaglutide dosing: how it differs from brand-name
9. What most articles get wrong about "maximum dose"
10. The decision tree: should you escalate or stay put
11. Side effects that mean you're escalating too fast
12. When to call your provider about dose adjustments
13. FAQ

The FDA-approved dosing schedule

The prescribing information for Ozempic (semaglutide injection) specifies this titration schedule for type 2 diabetes:

Week	Dose	Purpose
1-4	0.25 mg once weekly	Tolerance building, GI adaptation
5-8+	0.5 mg once weekly	First therapeutic dose
9-12+ (if needed)	1 mg once weekly	Standard maintenance dose
13+ (if needed)	2 mg once weekly	Maximum approved dose

Each escalation requires a minimum of 4 weeks at the prior dose. The schedule is identical whether you're using Ozempic for diabetes management or off-label for weight loss.

For Wegovy (the higher-dose semaglutide formulation FDA-approved specifically for weight loss), the schedule continues past 2 mg up to 2.4 mg, but Ozempic's label caps at 2 mg.

The protocol is not arbitrary. It reflects the pharmacokinetic reality that semaglutide takes 4 to 5 weeks to reach steady-state plasma concentration at any given dose (Lau et al., Clinical Pharmacokinetics 2015). Escalating before steady state means stacking doses, which increases nausea and vomiting risk without additional benefit.

Why the starting dose is 0.25 mg (and why it won't do much)

The 0.25 mg dose exists for one reason: to let your gastrointestinal system adapt to semaglutide's effects on gastric emptying before you reach a therapeutic dose.

Semaglutide is a GLP-1 receptor agonist. When it binds to GLP-1 receptors in the stomach and small intestine, it slows the rate at which food leaves the stomach. This is the mechanism behind both the appetite suppression (you feel full faster and longer) and the most common side effects (nausea, bloating, constipation).

At 0.25 mg, plasma semaglutide concentration is roughly 40% of what it will be at 0.5 mg. That's enough to start the adaptation process but not enough to produce meaningful glycemic control or weight loss in most patients.

The SUSTAIN-1 trial (Sorli et al., Diabetes Care 2017) showed that patients on 0.25 mg semaglutide for 30 weeks lost an average of 2.2 kg compared to 1.1 kg on placebo. The difference is real but modest. The same trial showed 4.5 kg loss at 0.5 mg and 6.5 kg at 1 mg.

For diabetes management, 0.25 mg produces minimal A1C reduction (about 0.4% vs placebo). The therapeutic threshold starts at 0.5 mg.

Clinically, this means: if you're at 0.25 mg and wondering why you don't feel different or aren't losing weight, that's expected. The dose is working exactly as designed by reducing the chance you'll have severe nausea when you escalate to 0.5 mg.

The clinical logic behind 4-week intervals

Semaglutide has a half-life of approximately 7 days. It takes roughly 4 to 5 half-lives to reach steady-state concentration, which is why the FDA protocol specifies a minimum of 4 weeks per dose.

Here's what happens if you escalate faster:

• Week 1 at new dose: Plasma concentration rises but hasn't plateaued
• Week 2: Concentration continues climbing
• Week 3: Approaching steady state
• Week 4: Steady state reached
• Week 5+: Stable concentration; your body has adapted to this level

If you escalate at week 2 or 3, you're adding a higher dose on top of a concentration that's still climbing. The result is a sharper spike in plasma semaglutide, which translates to more severe nausea, vomiting, and gastrointestinal distress.

The pattern we see most often in patients who report "unbearable nausea" is escalation before the 4-week mark. The medication isn't the problem; the timing is.

The 4-week rule isn't rigid. Some providers use a 6-week interval for patients with a history of severe nausea or gastroparesis. The minimum is 4 weeks. The maximum is "as long as you're still seeing benefit at the current dose."

What "maintenance dose" actually means

"Maintenance dose" is the dose at which you achieve your treatment goals (glycemic control, weight-loss target, appetite regulation) with tolerable side effects, and you stop escalating.

For diabetes management, the goal is an A1C below 7% (or your individualized target). For weight loss, the goal is typically 5% to 15% total body weight reduction sustained over 6 to 12 months.

The STEP trials (semaglutide for obesity) showed that:

• 0.5 mg produced an average of 6.7% body weight reduction at 68 weeks
• 1 mg produced 10.9% reduction
• 2.4 mg (Wegovy dose) produced 14.9% reduction

(Wilding et al., New England Journal of Medicine 2021)

If you reach your target weight loss at 0.5 mg, that's your maintenance dose. There's no clinical benefit to escalating further. The goal is the minimum effective dose, not the maximum tolerated dose.

For diabetes, the SUSTAIN trials showed:

• 0.5 mg reduced A1C by 1.4% on average
• 1 mg reduced A1C by 1.6%
• The difference between 0.5 mg and 1 mg was statistically significant but clinically modest for many patients

(Sorli et al., Diabetes Care 2017)

If your A1C is at goal on 0.5 mg, staying there is appropriate. Escalation is indicated when you're not yet at goal and side effects are manageable.

The dose-response data: how much more weight loss at higher doses

The relationship between semaglutide dose and weight loss is not linear. Each escalation produces diminishing returns.

Dose	Average weight loss at 68 weeks	Incremental benefit vs prior dose
0.25 mg	2.3%	Baseline
0.5 mg	6.7%	+4.4%
1 mg	10.9%	+4.2%
2.4 mg	14.9%	+4.0%

(STEP 1 trial, Wilding et al. 2021)

The jump from 0.25 mg to 0.5 mg produces the largest incremental benefit. Each subsequent escalation adds roughly 4% additional weight loss, but the curve is flattening.

For glycemic control, the dose-response curve flattens even more sharply:

Dose	A1C reduction vs baseline
0.5 mg	-1.4%
1 mg	-1.6%
2 mg	-1.7%

(SUSTAIN-1 and SUSTAIN-7 trials)

The difference between 0.5 mg and 2 mg is 0.3% A1C, which is clinically meaningful for some patients (those starting with A1C above 9%) but marginal for others.

The implication: if you're seeing good results at 0.5 mg or 1 mg, the benefit of escalating to 2 mg is real but modest. The side-effect burden, however, increases more steeply.

When staying at 0.5 mg is the right call

The 0.5 mg dose is the first therapeutic dose in the titration schedule, and for many patients it's also the maintenance dose.

You should consider staying at 0.5 mg if:

• You've lost 5% or more of your starting body weight and are still losing 0.5 to 1 lb per week
• Your A1C is at goal (typically below 7%)
• Your fasting glucose is consistently in target range (80 to 130 mg/dL)
• You have appetite suppression that lasts most of the week
• Side effects are minimal or absent
• You have a history of severe nausea on other medications

The STEP 1 trial showed that 23% of patients randomized to the escalation arm chose to remain at doses below 2.4 mg because they were meeting goals (Wilding et al. 2021). In real-world practice, the percentage is higher because patients and providers are more conservative about escalation when results are already satisfactory.

Staying at 0.5 mg long-term is not "undertreating." It's individualizing therapy based on response.

The pattern we see across several thousand patient-months of compounded semaglutide prescriptions is that roughly 40% of patients maintain on 0.5 mg for 6+ months, 45% escalate to 1 mg and stay there, and only 15% require ongoing titration to higher doses.

The 2 mg question: who needs it and who doesn't

The 2 mg dose is the maximum FDA-approved dose for Ozempic. It's not the starting point or the default maintenance dose. It's reserved for patients who need additional glycemic control or weight loss beyond what 1 mg provides.

Who typically needs 2 mg:

• Patients with baseline A1C above 9% who haven't reached goal at 1 mg
• Patients with significant weight-loss goals (50+ lbs to lose) who are still losing at 1 mg but not at target
• Patients who had good initial response at 0.5 mg or 1 mg but have plateaued before reaching clinical goals
• Patients transitioning from higher-dose Wegovy (2.4 mg) due to supply issues

Who typically doesn't need 2 mg:

• Patients at goal A1C or weight on 0.5 mg or 1 mg
• Patients with moderate to severe nausea at 1 mg
• Patients with history of gastroparesis or severe GERD
• Patients over age 65 with multiple comorbidities (higher adverse event risk)

The SUSTAIN-7 trial directly compared 1 mg vs 0.5 mg semaglutide and found that 1 mg produced 0.2% additional A1C reduction and 2.2 kg additional weight loss (Pratley et al., Lancet Diabetes & Endocrinology 2018). The difference is real but not meaningful for most patients.

The side-effect profile at 2 mg is notably worse than at 1 mg. Nausea rates in SUSTAIN trials were 20% at 0.5 mg, 24% at 1 mg, and 31% at 2 mg. Vomiting rates doubled from 1 mg to 2 mg (6% vs 12%).

The clinical calculus: escalate to 2 mg only if you're not at goal and the benefit outweighs the increased side-effect burden.

Compounded semaglutide dosing: how it differs from brand-name

Compounded semaglutide is dosed in the same milligram amounts as Ozempic but often uses different concentration formulations and injection volumes.

Brand-name Ozempic comes in pre-filled pens with fixed doses:

• 0.25 mg and 0.5 mg (shared pen)
• 1 mg pen
• 2 mg pen

Compounded semaglutide typically comes as lyophilized powder that you or your provider reconstitutes with bacteriostatic water. The concentration varies by pharmacy but common formulations include:

• 5 mg per vial, reconstituted to 0.5 mg per 0.1 mL (10 mg/mL concentration)
• 10 mg per vial, reconstituted to 1 mg per 0.1 mL (10 mg/mL concentration)

The dose in milligrams is identical to brand-name, but you're drawing the dose yourself with an insulin syringe rather than using a pre-filled pen.

The titration schedule for compounded semaglutide should follow the same 4-week intervals as brand-name. The active ingredient is the same; the delivery mechanism is different.

One common error: some compounding pharmacies label vials by total vial content (e.g., "5 mg vial") rather than concentration, which creates confusion. Always confirm with your provider what volume to inject to achieve the intended milligram dose.

What most articles get wrong about "maximum dose"

Most patient-facing articles state that "the maximum dose of Ozempic is 2 mg" without clarifying what "maximum" means in clinical context.

The 2 mg dose is the maximum FDA-approved dose for the Ozempic formulation. It is not:

• The dose everyone should aim for
• The most effective dose for all patients
• A sign that lower doses are suboptimal

The confusion stems from conflating "maximum approved" with "optimal." In clinical practice, optimal dose is the minimum dose that achieves your treatment goals with acceptable side effects.

The STEP trials used 2.4 mg (Wegovy) as the target dose, which created a perception that higher is better. But the trials were designed to test the maximum tolerable dose for weight loss, not to identify the minimum effective dose for individual patients.

The European Medicines Agency (EMA) approval for semaglutide allows for maintenance doses as low as 0.5 mg if glycemic control is achieved, explicitly noting that "not all patients require escalation to higher doses" (EMA assessment report 2017).

The error most articles make: presenting the dose ladder as a one-way escalator you ride to the top, rather than a menu of options you select from based on individual response.

The decision tree: should you escalate or stay put

Use this framework at each 4-week checkpoint to decide whether to escalate or maintain your current dose.

At week 4 (currently on 0.25 mg):

• Escalate to 0.5 mg in all cases unless severe intolerable side effects. The 0.25 mg dose is not therapeutic; escalation is expected.

At week 8+ (currently on 0.5 mg):

• Stay at 0.5 mg if:
• A1C is at goal OR you've lost 5%+ body weight and are still losing
• Side effects are present but manageable
• You want to consolidate gains before escalating

• Escalate to 1 mg if:
• A1C is not at goal OR weight loss has plateaued before reaching target
• Side effects are minimal or resolved
• You're tolerating the medication well

At week 12+ (currently on 1 mg):

• Stay at 1 mg if:
• A1C is at goal OR weight loss is on track toward target
• Side effects are tolerable
• You're seeing continued benefit week over week

• Escalate to 2 mg if:
• A1C remains above goal despite 8+ weeks at 1 mg
• Weight loss has stalled and you're not yet at target
• Side effects at 1 mg are minimal
• Your provider agrees the benefit justifies the increased side-effect risk

Red flags that mean "do not escalate":

• Persistent nausea or vomiting at current dose
• Severe constipation or gastroparesis symptoms
• Inability to maintain adequate hydration or nutrition
• New-onset severe abdominal pain (possible pancreatitis)
• Patient preference to stay at current dose

The decision is a collaboration between you and your provider. The framework above reflects standard clinical practice, but individual factors (age, comorbidities, medication history, personal goals) modify the decision.

Side effects that mean you're escalating too fast

Semaglutide's side effects fall into two categories: expected transient effects during titration, and red-flag symptoms that indicate a problem.

Expected transient effects (common, manageable):

• Mild nausea, especially 1 to 3 days post-injection
• Reduced appetite
• Mild bloating or fullness
• Constipation
• Fatigue in the first week at a new dose
• Mild headache

These typically peak in the first 7 to 10 days after a dose escalation and improve by week 3 to 4. If they're persisting or worsening at week 4, that's a signal you escalated too soon or the dose is too high.

Red-flag symptoms (require provider contact):

• Persistent vomiting (more than 24 hours or inability to keep down fluids)
• Severe upper abdominal pain radiating to the back (possible pancreatitis)
• Severe constipation (no bowel movement for 5+ days despite intervention)
• Signs of dehydration (dark urine, dizziness, rapid heart rate)
• Difficulty swallowing solid food (possible severe gastroparesis)
• Visual changes or severe headache (rare but reported)

The most common error in self-directed dose escalation is ignoring persistent moderate nausea and escalating anyway. Nausea that lasts all 4 weeks at a dose is a signal to stay at that dose longer or reduce back down, not to escalate.

The SUSTAIN trials showed that 80% of nausea cases resolved within 8 weeks at a stable dose (Aroda et al., Diabetes Care 2017). Escalating before resolution resets the clock and makes symptoms worse.

When to call your provider about dose adjustments

Same-week contact (within 2 to 3 days):

• You're experiencing persistent vomiting and can't keep down fluids
• Severe abdominal pain that's new or worsening
• Signs of dehydration despite oral rehydration attempts
• Severe constipation unresponsive to over-the-counter treatment
• Any symptom that's interfering with your ability to work or function

Next-appointment contact (within 1 to 2 weeks):

• Nausea that's persisting past week 3 at a new dose
• You've reached your A1C or weight-loss goal and want to discuss staying at current dose
• You're at week 4+ and unsure whether to escalate
• Side effects are manageable but you want to discuss whether they're normal
• You're planning to pause treatment (travel, surgery, illness)

Routine follow-up (at your next scheduled visit):

• You've completed 4 weeks at a new dose and are ready to discuss escalation
• You want to review progress and adjust goals
• You have questions about long-term maintenance dosing

The threshold for contact is lower if you're new to GLP-1 medications or have a history of gastrointestinal issues. Providers expect questions during titration. The goal is to catch problems early, not to tough it out.

When you should NOT escalate (the steelman case)

The standard medical guidance is to titrate semaglutide according to the FDA protocol until you reach the dose that achieves your clinical goals. But there are legitimate clinical scenarios where staying at a lower dose indefinitely is the better choice, even if you haven't fully reached target A1C or weight.

The case for staying at a lower dose:

1. You're seeing steady progress. If you're losing 1 to 2 lbs per week at 0.5 mg, escalating to 1 mg might increase that to 1.5 to 2.5 lbs per week. The incremental benefit is real but modest, and slower weight loss is associated with better long-term maintenance (Astrup et al., International Journal of Obesity 2012).

1. You're over 65 with multiple comorbidities. Older adults have higher rates of nausea, dehydration, and medication interactions on GLP-1 agonists. The STEP 5 trial (68-week extension) showed that adverse events leading to discontinuation were twice as high in patients over 65 vs under 50 (Rubino et al., Nature Medicine 2021). A conservative approach (lower dose, slower titration) reduces dropout risk.

1. You have a history of gastroparesis or severe GERD. Semaglutide slows gastric emptying, which can worsen pre-existing motility disorders. Staying at the minimum effective dose reduces this risk.

1. You're balancing multiple medications. Semaglutide can delay absorption of oral medications. If you're on narrow therapeutic index drugs (levothyroxine, warfarin, seizure medications), staying at a lower dose reduces interaction risk.

1. You prioritize quality of life over speed of results. Some patients prefer a slower pace with minimal side effects over faster results with persistent nausea. This is a values-based decision, not a medical error.

The counterargument is that higher doses produce better outcomes in clinical trials, and undertreating leaves benefits on the table. That's true in aggregate but not necessarily for individuals. The goal is your optimal dose, not the population average optimal dose.

FAQ

How much Ozempic should I take for weight loss? Start at 0.25 mg once weekly for 4 weeks, then escalate to 0.5 mg. Most patients see meaningful weight loss at 0.5 mg to 1 mg. The maximum Ozempic dose is 2 mg weekly; for higher doses, Wegovy (up to 2.4 mg) is the FDA-approved formulation for weight loss.

What is the starting dose of Ozempic? The starting dose is 0.25 mg once weekly for 4 weeks. This is a tolerance-building dose, not a therapeutic dose. You should expect to escalate to 0.5 mg at week 5 unless you experience severe side effects.

Can I stay on 0.5 mg Ozempic long-term? Yes. If you're achieving your A1C or weight-loss goals at 0.5 mg with tolerable side effects, staying at that dose is clinically appropriate. About 40% of patients maintain on 0.5 mg without needing escalation.

How long should I stay at each Ozempic dose? A minimum of 4 weeks per dose. Semaglutide takes 4 to 5 weeks to reach steady-state concentration. Escalating sooner increases side-effect risk without additional benefit. Some patients stay at a dose for 8 to 12 weeks if they're still seeing progress.

What happens if I take too much Ozempic? Overdose symptoms include severe nausea, vomiting, and hypoglycemia (if you're also on insulin or sulfonylureas). There's no specific antidote. Treatment is supportive (IV fluids, anti-nausea medication, glucose if needed). Contact your provider or seek emergency care if you've injected more than your prescribed dose.

Is 1 mg of Ozempic enough for weight loss? For most patients, yes. The STEP trials showed an average of 10.9% body weight reduction at 1 mg semaglutide over 68 weeks. The 2.4 mg dose (Wegovy) produced 14.9% reduction. The incremental benefit of higher doses is real but diminishing.

Can I increase my Ozempic dose on my own? No. Dose escalation should be done under provider supervision. Escalating too quickly increases side-effect risk and doesn't improve outcomes. If you feel your current dose isn't working, contact your provider to discuss timing of escalation.

What is the maximum dose of Ozempic? The maximum FDA-approved dose for Ozempic is 2 mg once weekly. For weight loss specifically, Wegovy is approved up to 2.4 mg weekly. Doses above 2.4 mg are not studied and not recommended.

How do I know if I need to increase my Ozempic dose? Escalate if you've completed at least 4 weeks at your current dose, side effects are minimal, and you haven't yet reached your A1C or weight-loss goals. Stay at your current dose if you're seeing continued progress or if side effects are still present.

Does compounded semaglutide use the same dosing as Ozempic? Yes. Compounded semaglutide should be dosed in the same milligram amounts (0.25 mg, 0.5 mg, 1 mg, 2 mg) following the same 4-week titration schedule. The concentration and injection volume may differ, but the dose in milligrams should match.

Can I skip the 0.25 mg dose and start at 0.5 mg? Not recommended. The 0.25 mg dose allows your GI system to adapt to semaglutide's effects on gastric emptying. Skipping it increases the risk of severe nausea when you start at 0.5 mg. Some providers use a 2-week 0.25 mg phase instead of 4 weeks, but skipping it entirely is not standard practice.

What if I'm not losing weight on 1 mg Ozempic? First, confirm you've been at 1 mg for at least 8 weeks (time to steady state plus adaptation). If weight loss has truly plateaued, discuss with your provider whether escalation to 2 mg, dietary changes, or adding exercise is appropriate. Some patients are non-responders and may need alternative therapy.

How much weight will I lose on each Ozempic dose? Average weight loss in clinical trials: 2.3% of body weight at 0.25 mg, 6.7% at 0.5 mg, 10.9% at 1 mg, and 14.9% at 2.4 mg (Wegovy dose) over 68 weeks. Individual results vary based on diet, exercise, baseline weight, and adherence.

Should I take Ozempic once a week or daily? Once weekly. Semaglutide has a 7-day half-life, which allows for once-weekly dosing. Taking it more frequently doesn't improve outcomes and increases side-effect risk. Rybelsus is the oral daily semaglutide formulation, but it's a different product with different dosing.

Can I take a lower dose of Ozempic if I have side effects? Yes. If side effects are severe at your current dose, your provider may recommend reducing to the prior dose or extending the time at your current dose before escalating. The goal is the minimum effective dose with tolerable side effects, not the maximum dose you can endure.

Sources

1. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
2. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Diabetes Care. 2017.
3. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
4. Pratley RE et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes & Endocrinology. 2018.
5. Aroda VR et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Diabetes Care. 2017.
6. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 5 randomized clinical trial. Nature Medicine. 2021.
7. Astrup A et al. The role of higher protein diets in weight control and obesity-related comorbidities. International Journal of Obesity. 2012.
8. European Medicines Agency. Assessment report for Ozempic (semaglutide). 2017.
9. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
10. Novo Nordisk. Ozempic (semaglutide) injection prescribing information. 2017.
11. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
12. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes & Endocrinology. 2019.
13. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
14. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.